Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
Skin Research and Technology · 2023-03 · 29 (3)
DOI: 10.1111/srt.13302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skin Research and Technology, online erschienen am 05.03.2023. Verfasst von Muazzez Cigdem Oba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Dermatology and Venereology, Istanbul, Turkey. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Atherosclerosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinical atherosclerosis in HS patients has not been previously investigated.
Objectives
In this study, we aimed to assess changes in biochemical parameters (fasting blood glucose and lipid levels) and carotid intima‐media thickness (CIMT) values in Hurley stage II and III HS patients undergoing treatment with TNF inhibitors.
Methods
This was a single center prospective study including 30 patients with Hurley stage II and III HS and 30 healthy controls (HCs). Baseline values of biochemical parameters and CIMT were compared to the values recorded after at least 6 months of TNF inhibitor therapy.
Results
CIMT values of the HS patients significantly exceeded those of HCs (for right p = 0.011 and for left p = 0.017). After at least 6 months of TNF inhibitor therapy, there was a statistically significant decrease in fasting blood glucose ( p = 0.001), whereas total cholesterol levels significantly increased ( p = 0.001). CIMT values also significantly increased (for right p = 0.02 and for left p = 0.01). Study limitations and conclusions Small sample size is limitation of the current study. Our study shows that patients with Hurley stage II and III HS undergoing TNF inhibitor therapy are under risk for progression of subclinical atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Dermatology and Venereology, Istanbul, Turkey.
- Istanbul University, Istanbul Medical Faculty, Department of Biostatistics, Istanbul, Turkey.
- Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey.
ORCID-Profile: Muazzez Cigdem Oba
Zitieren
APA
Oba, M. C., Askin, O., Gunver, M. G., Kocaarslan, G., Alis, D. C., & Engin, B. (2023). Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors. Skin Research and Technology, 29(3). https://doi.org/10.1111/srt.13302
Vancouver
Oba MC, Askin O, Gunver MG, Kocaarslan G, Alis DC, Engin B. Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors. Skin Research and Technology. 2023;29(3). doi:10.1111/srt.13302
BibTeX
@article{Oba2023,
author = {Oba, Muazzez Cigdem and Askin, Ozge and Gunver, Mehmet Guven and Kocaarslan, Gokce and Alis, Deniz Can and Engin, Burhan},
title = {Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors},
journal = {Skin Research and Technology},
year = {2023},
volume = {29},
number = {3},
doi = {10.1111/srt.13302}
}
EUVIMED